Table 1.
Demographic and clinical characteristics of HEAL study participants
| All participants (N=661) | Participants with weight change data (N=483) |
|||
|---|---|---|---|---|
| Baseline Characteristics | N (%) | Mean (SD) | N (%) | Mean (SD) |
| Race/Ethnicity/Study site | ||||
| Non-Hispanic White - Western Washington | 136 (20.6) | 136 (28.2) | ||
| Non-Hispanic White - New Mexico | 271 (41.0) | 258 (53.4) | ||
| Black | 163 (24.7) | 1 (0.2) | ||
| Hispanic | 70 (10.6) | 67 (13.9) | ||
| Other | 21 (3.2) | 21 (4.4) | ||
| Age, years | ||||
| 29–49 | 195 (29.5) | 123 (25.5) | ||
| 50–59 | 255 (38.6) | 189 (39.1) | ||
| 60–69 | 146 (22.1) | 114 (23.6) | ||
| 70+ | 65 (9.8) | 57 (11.8) | ||
| Mean age | 55.5 (10.0) | 56.6 (10.2) | ||
| Educationa | ||||
| High School or less | 166 (25.2) | 103 (21.3) | ||
| Some college | 241 (36.5) | 166 (34.4) | ||
| College grad | 131 (20.0) | 111 (23.0) | ||
| Grad school | 122 (18.5) | 103 (21.3) | ||
| Stage at diagnosis | ||||
| in situ | 154 (23.3) | 120 (24.8) | ||
| Local | 367 (55.5) | 278 (57.6) | ||
| Regional | 140 (21.2) | 85 (17.6) | ||
| Estrogen and Progesterone Receptor status | ||||
| ER positive / PR positive | 285 (43.1) | 236 (48.9) | ||
| ER positive / PR negative | 56 (8.5) | 46 (9.5) | ||
| ER negative / PR positive | 12 (1.8) | 3 (0.6) | ||
| ER negative / PR negative | 79 (12.0) | 47 (9.7) | ||
| Unknown | 229 (34.6) | 151 (31.3) | ||
| Primary treatment type | ||||
| Any chemotherapy | 198 (30.0) | 132 (27.3) | ||
| Surgery/Radiation | 256 (38.7) | 210 (43.5) | ||
| Surgery only | 207 (31.3) | 141 (29.2) | ||
| Time Since Diagnosis, months* | ||||
| Diagnosis to the 24-month assessment | 30.7 (3.7) range 18.3–48.2 |
29.8 (2.8) range 18.3–43.7 |
||
| Diagnosis to the quality of life (QOL) assessment | 40.8 (6.6) range 23.4–63.8 |
39.8 (6.4) range 23.4–57.6 |
||
| New Mexico | 42.8 (5.4) range 32.4–57.6 |
42.8 (5.3)range 32.4–57.6 | ||
| Los Angeles | 43.7 (6.3) range 33.9–63.8 |
N/A | ||
| Western Washington | 33.9 (3.7) range 23.4–46.0 |
33.8 (3.7) range 23.4–46.0 |
||
| 30-month assessment | ||||
| Marital statusb | ||||
| Partnered | 395 (59.8) | 314 (65.0) | ||
| Not partnered | 263 (39.8) | 166 (34.3) | ||
| Menopausal status | ||||
| Pre | 116 (17.6) | 87 (18.0) | ||
| Post | 506 (76.6) | 372 (77.0) | ||
| Unclassifiable | 39 (5.9) | 24 (5.0) | ||
| Medication use | ||||
| Tamoxifen | 301 (45.5) | 227 (47.0) | ||
| Antidepressants/anxiolytics/hypnotics/sedatives | 135 (20.4) | 115 (23.8) | ||
| Anti-inflammatory drugs | 371 (56.1) | 292 (60.5) | ||
| Number of Comorbid conditions | ||||
| 0 | 228 (34.5) | 178 (36.9) | ||
| 1 | 222 (33.6) | 158 (32.7) | ||
| 2+ | 211 (31.9) | 147 (30.4) | ||
| Diabetes | 68 (10.3) | 42 (8.7) | ||
| Arthritis | 256 (38.7) | 189 (39.1) | ||
| Cardiovascular disease (angina, myocardial infarction, congestive heart failure, stroke) | 79 (12.0) | 50 (10.4) | ||
| Lifestyle factors | ||||
| Smoking | ||||
| Current | 77 (11.7) | 52 (10.8) | ||
| Former | 263 (39.8) | 199 (41.2) | ||
| Never | 321 (48.6) | 232 (48.0) | ||
| Moderate-to-vigorous physical activity, METs /week | 12.4 (18.3) | 13.6 (19.4) | ||
| Anthropometrics | ||||
| Underweight (BMI < 18.5 kg/m2) | 8(1.2) | 6 (1.2) | ||
| Normal weight (18.5 ≤ BMI < 25 kg/m2) | 245 (37.1) | 204 (42.2) | ||
| Overweight (25 ≤ BMI < 30 kg/m2) | 209 (31.6) | 160 (33.1) | ||
| Obese (BMI ≥ 30 kg/m2) | 199 (30.1) | 113 (23.4) | ||
| Mean BMI, kg/m2 | 28.0 (6.3) | 27.0 (5.6) | ||
| Weight change from baseline to 24-mo follow-up† | ||||
| Lost weight (≤ −5%) | N/A | 45 (9.3) | ||
| Maintained weight (weight change < 5%) | N/A | 307 (63.6) | ||
| Gained weight (≥ 5%) | N/A | 131 (27.1) | ||
| Inflammatory biomarker | ||||
| C-reactive protein (mg/L) | 4.4 (8.4) | 3.6 (5.0) | ||
| C-reactive protein > 3 mg/L | 254 (38.4) | 169 (35.0) | ||
*
n=7 were missing information on 24-month follow-up date
a
n=1 missing for all participants.
b
n=3 missing for all participants and for participants with weight change data.